Latest Conference Articles

September 17th 2017, 10:18pm

International Liver Cancer Association Annual Conference

First-line therapy with lenvatinib continued to be noninferior in overall survival and achieve significant improvements in progression-free survival, time to progression, and objective response rate compared with sorafenib for patients with unresectable hepatocellular carcinoma.

September 16th 2017, 11:13pm

Lynn Sage Breast Cancer Symposium

Health investment is failing to match the challenge presented by a growing cancer burden in countries at all economic levels, enhancing the need for new approaches that help optimize the delivery of care.

September 16th 2017, 10:15pm

Lynn Sage Breast Cancer Symposium

There is a significant transformation underway in the treatment of breast cancer as research advances and new laboratory techniques continue to shrink the so-called "undruggable genome."

September 16th 2017, 9:23pm

Lynn Sage Breast Cancer Symposium

Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses adjuvant therapy for elderly patients with HER2-positive or triple-negative breast cancer (TNBC).

September 16th 2017, 9:02pm

International Liver Cancer Association Annual Conference

Hepatocyte pERK-positive immunostaining and microvascular invasion were independent prognostic factors of recurrence-free survival for patients with hepatocellular carcinoma treated with adjuvant sorafenib; however, a predictive biomarker for recurrence was not uncovered.

September 16th 2017, 8:44pm

International Liver Cancer Association Annual Conference

Precision screening for hepatocellular carcinoma (HCC) could improve on current screening techniques through its risk-stratifying approach.

September 16th 2017, 8:17pm

Lynn Sage Breast Cancer Symposium

Patients have a hard time with artificially induced menopause and some research suggests it may have a negligible effect on the success of their treatment.

September 16th 2017, 8:07pm

Lynn Sage Breast Cancer Symposium

Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses treatment for premenopausal patients with breast cancer.

September 16th 2017, 3:59pm

International Liver Cancer Association Annual Conference

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the significance of the phase III trial of frontline lenvatinib (Lenvima) versus sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

September 16th 2017, 1:58pm

International Liver Cancer Association Annual Conference

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses how immunotherapy agents will eventually fit into the paradigm of hepatocellular carcinoma. (HCC).

September 16th 2017, 3:18am

International Liver Cancer Association Annual Conference

Theodore H. Welling, MD, shares insight on the top presentations at the ILCA meeting, and how he believes the future will look for the treatment of HCC.

September 16th 2017, 2:08am

Lynn Sage Breast Cancer Symposium

José Baselga, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses biomarker research for patients with breast cancer.

September 16th 2017, 2:06am

Lynn Sage Breast Cancer Symposium

Benjamin O. Anderson, MD, a surgical oncologist at the Seattle Cancer Care Alliance, discusses the biggest unmet need for patients with breast cancer in low- and middle-income countries.

September 16th 2017, 1:46am

International Liver Cancer Association Annual Conference

Robert Montal, MD, visiting researcher, Icahn School of Medicine, Mount Sinai Hospital, discusses advancements regarding systemic therapies in the field of hepatocellular carcinoma (HCC).

September 16th 2017, 1:46am

International Liver Cancer Association Annual Conference

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, shares insight on some current and emerging agents in the field of hepatocellular carcinoma (HCC).

September 16th 2017, 1:45am

International Liver Cancer Association Annual Conference

The 11th International Liver Cancer Association Annual Conference, taking place September 15 to 17 in Seoul, South Korea, is showcasing multidisciplinary findings across the field of hepatocellular carcinoma.

September 16th 2017, 1:05am

Lynn Sage Breast Cancer Symposium

Multigene panel testing offers a new but often puzzling tool for breast cancer treatment, since the results are often difficult to interpret, both for relative risk and risk management.

September 16th 2017, 12:10am

Lynn Sage Breast Cancer Symposium

Even with advancements in technology, the prospect of artificial intelligence treating patients with cancer still remains out of reach. At least, for now.

September 15th 2017, 11:54pm

Lynn Sage Breast Cancer Symposium

Extra vigilance, careful management, and an emphasis on empathy makes treating cancer pain more effective during an opioid addiction epidemic.

September 15th 2017, 12:09am

Lynn Sage Breast Cancer Symposium

William F. Symmans, MD, professor of Pathology, The University of Texas MD Anderson Cancer Center, discusses the staging system for patients with breast cancer.